Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Russia-based drug-maker Pharmstandard has decided to spin-off its branded over-the-counter business (Branded OTC), into a separate entity whose shares will be proportionally distributed among the shareholders of the company.
Subscribe to our email newsletter
Further details of the new venture are awaited, although the company conveyed that it will call a shareholder meeting in accordance with legislation of Russian Federation and with the company’s Charter.
Most recently, the company was mulling to divest its $2.5bn OTC business, and the proposed acquirer will have the opportunity to exploit the country’s growing market.
The launch of OTC business will allow Pharmstandard to concentrate on its prescription medicines, whose revenues increased by 33% to about $181.6m in 2012, as reported by Reuters.
The OTC segment revenues declined by 4.5% to $453.8m year-over-year.
In a separate release, the company said that it has inked an agreement to acquire 100% of Singapore-based company Bever Pharmaceutical in a deal valued at $630m.